Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexamethasone sodium phosphate sustained release - Taiwan Liposomal Company

Next Previous
Drug Profile

Dexamethasone sodium phosphate sustained release - Taiwan Liposomal Company

Alternative Names: Dexamethasone sustained release - Taiwan Liposomal Company; TLC-599

Latest Information Update: 10 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiwan Liposome Company
  • Class Anti-inflammatories; Antiallergics; Antiemetics; Antihyperglycaemics; Antineoplastics; Antirheumatics; Corticosteroids; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Ketones; Non-opioid analgesics; Phosphates; Pregnadienetriols; Small molecules; Sodium compounds; Vestibular disorder therapies
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Osteoarthritis

Most Recent Events

  • 10 Jan 2025 Dexamethasone sodium phosphate sustained release is still in phase-III trials for Osteoarthritis in USA and Australia (Intra-articular)
  • 23 Nov 2023 Interim safety and efficacy data from a phase III EXCELLENCE trial in osteoarthritis released by Taiwan Liposome Company
  • 10 Nov 2023 Efficacy and adverse events data from a phase III EXCELLENCE trial in osteoarthritis presented at the ACR Convergence 2023 (ACR/ARP-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top